Home Cart Sign in  
Chemical Structure| 1889279-16-6 Chemical Structure| 1889279-16-6

Structure of A-485
CAS No.: 1889279-16-6

Chemical Structure| 1889279-16-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

A 485 is a potent and selective p300/CREB-binding protein (CBP) HAT domain inhibitor with IC50 of 2.6 and 9.8 nM for the CBP-bromodomain HAT-C/H3 (BHC) and p300-BHC domains, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of A-485

CAS No. :1889279-16-6
Formula : C25H24F4N4O5
M.W : 536.48
SMILES Code : O=C(N(CC1=CC=C(F)C=C1)[C@@H](C)C(F)(F)F)CN(C2=O)C(O[C@]32CCC4=C3C=CC(NC(NC)=O)=C4)=O
MDL No. :MFCD31619258
InChI Key :VRVJKILQRBSEAG-LFPIHBKWSA-N
Pubchem ID :118958122

Safety of A-485

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of A-485

epigenetics

Isoform Comparison

Biological Activity

Target
  • p300/CBP

    p300 HAT, IC50:0.06 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
RAW264.7 cells 2.2 μM, 6.6 μM, 13.2 μM, 20 μM 4 hours or 24 hours A-485 inhibited LPS-induced inflaμMatory cytokine expression in a concentration-dependent manner PMC6857059
Primary BMDM cells 2.2 μM, 6.6 μM, 13.2 μM, 20 μM 4 hours or 24 hours A-485 impaired LPS-induced pro-inflaμMatory gene expression at both mRNA and protein levels PMC6857059
HCC2429 10 µM 72 hours Screening for NMC-selective inhibitors, A-485 showed strong anti-proliferative activity in HCC2429 cells PMC7286816
Patu8988T 10 µM 72 hours Screening for NMC-selective inhibitors, A-485 did not show strong anti-proliferative activity in Patu8988T cells PMC7286816
QGP-1 10 µM 72 hours Screening for NMC-selective inhibitors, A-485 did not show strong anti-proliferative activity in QGP-1 cells PMC7286816
Human bronchial/tracheal epithelial cells (HBTEC) 10 μM 2 hours To investigate the effect of CBP/p300 acetyltransferase activity on H3K18/27 acetylation, results showed that A-485 treatment significantly reduced H3K18/27 acetylation PMC8009678
Primary mouse hepatocytes 3 μM 18 hours A-485 significantly decreased the mRNA expressions of key lipogenesis and cholesterol synthesis genes PMC7486386
Primary mouse hepatocytes 3 μM 24 hours A-485 significantly inhibited 8-Br-cAMP-stimulated glucose production PMC7486386
HuH-7 1 μM/L A-485 significantly inhibited the glycine/serine metabolic pathway in HuH-7 cells and suppressed the expression of TRIM71 and CEBPA PMC11388079
HuH-6 1 μM/L A-485 significantly inhibited the glycine/serine metabolic pathway in HuH-6 cells and suppressed the expression of TRIM71 and CEBPA PMC11388079
human embryonic stem cell-derived TNNT2+ CMs 0.5 µM 60 hours Induced dedifferentiation of cardiomyocytes into regenerative cardiac cells (RCCs), characterized by increased ISL1 expression and downregulation of cardiomyocyte markers TNNT2 and MYL2 PMC11627505

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SCID male mice LuCaP-77 CR xenograft model intraperitoneal injection 1.5 × 10^11 genome copies Single injection, lasting 4 weeks A-485 induced 54% tumor growth inhibition (TGI) after 21 days of dosing (p<0.005 as compared to vehicle control). PMC6050590
C57BL/6J mice LPS/D-galactosamine-induced acute liver injury model Intraperitoneal injection 100 µM Single dose, lasting 80 minutes A-485 significantly alleviated histopathological abnormalities, lowered plasma aminotransferases, and improved the survival rate in LPS/GalN-induced acute liver injury mice PMC6857059
C57BL/6 mice Normal chow diet (NCD) and high-fat diet (HFD) models Intraperitoneal injection twice daily for 21 days A-485 significantly reduced body weight and fat mass in mice and improved glucose metabolism PMC7486386
mice MLL-r AML xenograft models intraperitoneally 100 mg/kg Single dose, lasting 4 hours A-485 significantly reduced the engraftment of human CD45+ leukemia cells in the peripheral blood and extended the survival time. PMC11063202
Mice Ischemic stroke model Intraperitoneal injection 20 mg/kg/day Once daily for 1 week A-485 preconditioning significantly reduced protein lactylation levels in ischemic brains at 6 h post-cerebral ischemia, improved neuronal survival, decreased glial activation, alleviated brain edema and histological structure alterations, reduced infarct volumes, extended reperfusion time, and improved functional recovery in mice with ischemic stroke. PMC11303085
Mice Maver-1 and Z-138 xenograft models A-485: intraperitoneal, idelalisib: oral 100 mg/kg once daily for 14 days Significantly suppressed tumor growth and reversed the unsustained inhibition in PI3K downstream signaling PMC8791947
Mouse Xenograft mouse model Intraperitoneal injection 50 mg/kg Single dose, continuous observation A-485 combined with ATRA significantly inhibited tumor growth in HuH-6 xenograft mouse models and prolonged survival time PMC11388079
mice myocardial infarction model intraperitoneal injection A-485: 50 mg/kg, idelalisib: 30 mg/kg Once daily for 21 days 2C-induced regenerative cardiac cells (RCCs) significantly improved cardiac function and survival rate post-myocardial infarction PMC11627505

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.86mL

0.37mL

0.19mL

9.32mL

1.86mL

0.93mL

18.64mL

3.73mL

1.86mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories